Study Shows Linaclotide Beneficial for Pediatric Functional Constipation
The phase 3 trial included patients 6 to 17 years of age who fulfilled modified Rome III Criteria for child/adolescent functional constipation.
Constipation
Vibrant, a Drug-Free Treatment for Chronic Idiopathic Constipation, Gets FDA Clearance
The marketing authorization was supported by data from a pivotal clinical trial in 312 patients with chronic idiopathic constipation.
Antacid, Constipation Products Recalled Due to Microbial Contamination
The recalled lots were distributed to Major Pharmaceuticals Distribution Center between July 1, 2020 and October 31, 2021.
Elobixibat Improves Constipation in Chronic Kidney Disease
Improvement also seen in lipid metabolism, with increase in LDL cholesterol and decrease in HDL cholesterol
Microbial Contamination Prompts Recall of Senna Syrup
The recalled lot of Senna Syrup 8.8mg/5mL; NDC # 50268-731-24; Lot AM1115S; Expiration Date 01/2023, was distributed to the wholesaler, AvKare.
Linzess Labeling Updated Based on New Pediatric Data
The updated label now states that the treatment is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
Study Suggests Limited Efficacy of OTC Meds for Chronic Idiopathic Constipation
Results showed that the majority of patients expressed dissatisfaction with the effect of the OTC agent on constipation and CIC-specific abdominal symptoms.
Generic Version of Amitiza Now Available
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
Motegrity Approved for Chronic Idiopathic Constipation in Adults
Shire announced that the Food and Drug Administration (FDA) has approved Motegrity (prucalopride) tablets for the treatment of adults with chronic idiopathic constipation (CIC).
New Treatment for Opioid-Induced Constipation Approved
The Company’s petition for the descheduling of Symproic is currently being evaluated by the Drug Enforcement Agency (DEA).
